Document:

Exhibit 10.31

 

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 240.24b-2

 

LICENSE AGREEMENT

 

THIS EXCLUSIVE LICENSE
AGREEMENT (the “Agreement”) is made this 21 day of June, 2006 by and between UNIVERSITA DEGLI STUDI DI ROMA
“LA SAPIENZA” (fiscal code 80209930587, VAT No. 02133771002), located in Rome, piazzale Aldo Moro, 00185,
Rome, Italy (“LICENSOR”), and CAPRICOR INC., a corporation organized and existing under the laws of the State
of Delaware and with principal place of business located at 2415 Old Bosley Road, Lutherville, Maryland 21093, United States of
America (“LICENSEE”). (LICENSOR and LICENSEE each a “Party”; and together the “Parties” herein).

 

WHEREAS, LICENSOR is
owner by assignment from [...***...]; and

 

WHEREAS, LICENSOR is
owner by assignment from the Inventors of all their right, title and interest in the TECHNOLOGY as defined below; and

 

WHEREAS, LICENSEE wishes
to obtain an exclusive license in the TERRITORY to practice the above-referenced invention covered by LICENSED PATENT RIGHTS in
the United States and in certain foreign countries, and to make, have made, use, have used, sell and have sold in the commercial
market the products made in accordance therewith; and

 

WHEREAS, LICENSOR wishes
to grant such a license to LICENSEE in accordance with the terms of the Agreement.

 

NOW, THEREFORE in consideration
of the foregoing premises, the Parties agree as follows:

 

I.
DEFINITIONS

 

		1.1	AFFILIATES means any corporation, firm, partnership or other entity, whether de jure or
de facto, which directly or indirectly owns, is owned by or is under common ownership with a party to this Agreement to
the extent of at least fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by
a foreign corporation in a particular jurisdiction) having the power to vote on or direct the affaire of the entity.

 

		1.2	EFFECTIVE DATE is the date first set Forth above,

 

		1.3	FIELD OF USE means all fields.

 

		1.4	LICENSED PATENT RIGHTS means patent rights to any subject matter claimed in or covered by any of
the following: [...***...] (both applications together the “Parent
Applications” as set forth in Appendix A); includes any continuations and divisionals, continuations-in-part, patents issuing
thereon and all reissues, re-examinations, divisions or extensions thereof, and any and all foreign patents and patent applications

 

*Confidential Treatment Requested

 

    	 

    	 

    

 

		1.5	LICENSED PRODUCT means any process or method, material, compositions, drug, or other product, the
manufacture, use, or sale of which would constitute, but for the license granted to LICENSEE pursuant to this Agreement, an infringement
of a claim of Patent Rights (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe).

 

		1.6	NET SALES REVENUES means the gross sales revenues and fees billed by LICENSEE and AFFILIATES from
the sale of Licensed Product less trade discounts allowed, refunds, returns and recalls, amounts allowed for bad debt, outward
bound transportation and delivery charges, transportation and product liability insurance, government- mandated retroactive price
reductions, tariff duties, and sales taxes.

 

In the event
that LICENSEE and/or AFFILIATES sell LICENSED PRODUCT(S) in combination with a device for delivery or as part of a kit and such
other devices or components (collectively “Other Components”), then NET SALES REVENUES for purposes of royalty payments
shall be calculated using one of the following methods: (x) if all LICENSED PRODUCT(S) and Other Components contained in the
combination are available separately, then NET SALES REVENUES, shall be calculated by multiplying the NET SALES REVENUES of the
combination by the fraction A/A+B, where A is the invoice price of all LICENSED PRODUCT(S) in the combination and B is the invoice
price of all Other Components in the combination; (y) if the combination includes Other Components which are not sold separately
(but all LICENSED PRODUCT(S) contained in the combination are available separately), then NET SALES REVENUES shall be calculated
by multiplying the NET SALES REVENUES of the combination by the fraction A/C, where A is defined above and C is the invoice price
of the combination; and (z) if the LICENSED PRODUCT(S) and the Other Components in the combination are not sold or available
separately, then NET SALES REVENUES for purposes of determining royalties on the combination shall be calculated by multiplying
NET SALES REVENUES of the combination by the fraction D/D+E, where D is the fully burdened manufacturing cost of LICENSED PRODUCT(S)
at the point of assembly into the combination and E is the fully burdened manufacturing cost of the Other Components included in
the combination at such point.

 

In the event
any LICENSED PRODUCT(S) shall be sold by Company to an AFFILIATE or among AFFILIATES for subsequent resale to an unaffiliated third
party, then the royalty due hereunder shall be based upon the greater of: (a) NET SALES REVENUES received by Company from
the AFFILIATE and (b) NET SALES REVENUES received by the AFFILIATE from the purchaser of such LICENSED PRODUCT(S).

 

		1.7	TERRITORY means worldwide.

 

    	2

    	 

    

 

II.
 

 

II.
license grant

 

		2.1	LICENSOR hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions hereof,
an exclusive right in the FIELD OF USE, in the TERRITORY to make, have made, use, have used, export, import, offer for sale, sell,
and have sold the Licensed Products in Italy, the United States, and worldwide in the Exclusive Field, subject to Retained Rights
(below) and freely and fully sublicenseable-LICENSEE shall have a [...***...] first right of negotiation to have the
reasonable opportunity to license from LICENSOR any new and separate patent applications assigned to LICENSOR by any of the Inventors,
not falling within the definition of “PATENT RIGHTS,” but utilizing (or enabling the use of) cardiac stem cells in
cardiac care.

 

		2.2	LICENSOR also grants to LICENSEE the right to issue sublicenses to third parties to make, have
made, export, import, use, have used, sell, have sold, and offer for sale LICENSED PRODUCTS as long as LICENSEE has current exclusive
rights thereto under this Agreement and shall compensate LICENSOR pursuant to Section 3.4 of this Agreement for sublicenses.

 

		2.3	LICENSOR, subject to Section 10.4, reserves and retains the right (and the rights granted to LICENSEE
herein shall be limited accordingly) to make, use, and practice for its own internal research by (only) the Inventors and/or for
educational purposes the inventions falling within the scope of the LICENSED PATENT RIGHTS.

 

III.
FINANCIAL OBLIGATIONS, PAYMENT AND REPORTS

 

		3.1	LICENSEE shall pay to LICENSOR a License Issue Fee of [...***...]:

 

- 
the first installment of [...***...] shall be transferred within [...***...] immediately following
the EFFECTIVE DATE;

- 
the second installment of [...***...] will be due and payable within [...***...] following the
EFFECTIVE DATE.

 

		3.2	LICENSEE shall assure to LICENSOR Minimum Annual Royalties Guaranteed described below:

- 
[...***...] per annum for the rolling two years immediately starting with the third coming year since the
EFFECTIVE DATE;

- 
[...***...] per annum starting with the third year and during the period this Agreement is in force as
set forth below.

 

Minimum Annual Royalties
are fully creditable.

 

		3.3	LICENSEE shall pay LICENSOR [...***...] of all royalties received as a result of sublicenses
granted pursuant to Section 2.2 of this Agreement (which royalties for the purpose of this Section 3.3 shall be “net”
of any third-party royalties paid by LICENSEE (or by any AFFILIATE or sublicensee on behalf of LICENSEE) for any such third-party
royalties due to be paid under a license agreement from any such third party to LICENSEE).

 

*Confidential Treatment Requested

 

    	3

    	 

    

 

		3.4	Royalties shall accrue when LICENSED PRODUCTS, with respect to the NET SALES REVENUES of which
earned royalty payments are required under this Agreement, are invoiced to the customer by LICENSEE or an AFFILIATE.

 

		3.5	LICENSEE shall provide LICENSOR with semestral reports as to its R&D, regulatory, and commercialization
progress.

 

		3.6	LICENSEE shall be responsible for the collection and payment of all royalties owed to LICENSOR
resulting from any sublicense(s) granted by LICENSEE.

 

		3.7	LICENSEE understands and agrees that a declaration of invalidity by a court of competent jurisdiction
of any patent under the LICENSED PATENT RIGHTS shall not be prejudicial to this Agreement with respect to royalties previously
paid to LICENSOR by LICENSEE. Therefore, should any such patent be declared invalid, LICENSOR shall have no obligation to repay
to LICENSEE the license issue fee nor any portion of the royalties already received from LICENSEE in accordance with the provisions
of this Agreement.

 

		3.8	LICENSEE shall maintain at its principal office usual books of account and records showing its
actions under this Agreement. Such books and records shall be open to inspection and copying, upon reasonable notice during usual
business hours by an independent certified public accountant reasonably acceptable to LICENSEE for two (2) years after
the calendar quarter to which they pertain, for purposes of verifying the accuracy of the royalties paid by LICENSEE under this
Agreement at LICENSOR’s expense. Such audits shall not occur more frequently than once during any period of one year. LICENSOR
and any such independent certified public accountant shall treat LICENSEE’s books and records as confidential.

 

		3.9	In the event that any payment due under this Agreement is not made when due, the payment shall
accrue interest from the date due at the rate of 0.8% per month; provided, however, that in no event shall such rate exceed
the maximum legal annual interest rate.

 

		3.10	Until such time as LICENSOR provides LICENSEE with written notice to the contrary, all payments
to the LICENSOR by LICENSEE pursuant to this Agreement shall be paid [...***...].

 

		3.11	Royalties and payments arising from sublicensee royalties shall be paid to LICENSOR on a quarterly
basis on or before each April 30, My 31, October 31, and January 31 for the preceding quarter ending upon March 31,
June 30, September 30, and December 31, respectively, and shall be paid with a report detailing such royalties and
payments.

 

		3.12	In accordance with Sections 3.1, 3.2 and 3.3 above, License Issue Fee and Royalties due by LICESEE
to the LICENSOR shall be secured by a first demand irrevocable bank guarantee (with a branch in Italy). The bank guarantee shall
be presented to LICENSOR within the first rolling month since the EFFECTIVE DATE and shall terminate automatically in any case
of termination of the Agreement.

 

IV.
PATENT PROSECUTION

 

 

*Confidential Treatment Requested

 

    	4

    	 

    

 

		4.1	During the term of this Agreement, LICENSOR shall control patent filing, prosecution and maintenance,
upon consultation with LICENSEE. Both Parties shall instruct patent counsel to cross copy each other with copies of all documents
(or drafts thereof) pertaining to the filing, prosecution or maintenance of the Patent Rights to enable both parties to have a
meaningful opportunity to review and comment thereon.

 

		4.2	During the period that this Agreement is in force:

		a.	If LICENSEE desires to have a patent application filed in any country(ies) in which a patent application
is not then being prosecuted LICENSEE shall notify LICENSOR, in writing, and shall bear the responsibility to file, prosecute such
applications and maintain the resulting patents.

		b.	LICENSOR shall diligently prosecute and maintain the LICENSED PATENT RIGHTS (including any additional
patents included by virtue of Section 4.2a herein) using its counsel of choice. LICENSOR shall provide LICENSEE with copies of
all relevant documentation so that LICENSEE may be informed and apprised of the continuing prosecution and LICENSEE agrees to keep
such documentation confidential.

		c.	All invoices relating to the reasonable costs of prosecution and maintenance of patents in the
Selected Countries shall be sent directly to LICENSEE by LICENSOR’s counsel of choice. LICENSEE shall have thirty (30)
days from the date of LICENSEE’s receipt of such invoices to make payment to LICENSOR’s counsel of choice.

		d.	It shall be the responsibility of LICENSOR, whether directly or through LICENSOR’s counsel
of choice, to notify and keep LICENSEE informed of the status of all pending and issued claims under the LICENSED PATENT RIGHTS.

 

V.
INFRINGEMENT

 

		5.1	Each Party shall promptly notify the other Party in writing of any suspected infringement(s) of
the LICENSED PATENT RIGHTS and shall inform the other Party of any evidence of such infringement(s).

 

		5.2	LICENSOR shall have the first right to enforce any patent within Patent Rights and the Field against
any infringement or alleged infringement. LICENSOR shall reasonably cooperate in any such litigation at LICENSEE’s expense,
including being named as a party plaintiff. If LICENSOR does not take all necessary action to enforce a particular patent, LICENSEE
has the option (but not the obligation) to do so.

 

VI.
TERM AND TERMINATION

 

		6.1	This Agreement, unless extended or earlier terminated as provided herein, shall remain in effect
until the later of: (a) the last claim of any patent or patent application comprising LICENSED PATENTS RIGHTS has expired
or been abandoned

 

		6.2	This AGREEMENT may be terminated immediately by either party upon written notice should the other
party become insolvent, file a petition under any bankruptcy or insolvency act, or have any such petition filed against it, or
offer any general composition to its creditors, because of the happening of such act, event or offer.

 

    	5

    	 

    

 

		6.3	LICENSEE may terminate, for any reason, upon giving LICENSOR ninety (90) days written notice.
Prior obligations, such as payment of owed royalties, are not affected by termination.

 

		6.4	Termination of this Agreement shall not terminate LICENSEE’s obligation to file all reports
and to pay all royalties with respect to LICENSED PRODUCTS which shall have accrued hereunder.

 

		6.5	All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, as amended (the “Code”), licenses of rights
to “intellectual property” as defined under Section 101 of the Code. The parties agree that LICENSEE is a licensee
of such rights under this Agreement and shall retain and may fully exercise all rights under the Code. The parties further agree
that, in the event of the commencement of a bankruptcy proceeding by or against LICENSOR or its assignee under the Code, LICENSEE
shall be entitled to (x) take control of the patent prosecution of the Patent Rights and (y) receive a complete duplicate
of (or complete access to, as appropriate) any such intellectual properly and all embodiments of such intellectual property. Such
intellectual property and embodiments, if not already in LICENSEE’s possession, shall be, within ten (10) days
of the commencement of such proceeding, delivered to it upon LICENSOR’s receipt of a request therefore, unless LICENSOR (or
a trustee on behalf of LICENSOR) elected to continue to perform all of its obligations under this Agreement. Nothing herein shall
constitute LICENSEE’s acquiescence or agreement that all or any portion of this Agreement is subject to rejection.

 

VII.
BREACH AND CURE

 

		7.1	In addition to applicable legal standards, LICENSEE shall be in material breach of this Agreement
for failure to pay amounts due pursuant to Section III (FINANCIAL OBLIGATIONS).

 

		7.2	Either party shall have the right to cure its material breach. The cure shall be effected within
a reasonable time but in no event later than ninety (90) days after written notice of breach given by the non-breaching party.

 

VIII.
WARRANTY

 

		8.1	LICENSOR represents and warrants that: (a) it owns the entire right, title and interest in
the patent applications or patents comprising the LICENSED PATENT RIGHTS in the FIELD OF USE; (b) it has the power and authority
to grant licenses under said LICENSED PATENT RIGHTS; (c) it has not made and shall not make any commitments to third parties
inconsistent with or in derogation of this Agreement; (d) it shall advise LICENSEE within thirty (30) days (or more promptly
if and as practicable) of learning of any legal action or proceeding being instituted against LICENSOR relating to the LICENSED
PATENT RIGHTS; and, (e) to the knowledge of LICENSOR, the LICENSED PATENTS RIGHTS are valid and enforceable and have not been
challenged by a third party in any judicial or administrative proceeding.

 

    	6

    	 

    

 

		8.2	Each Party represents and warrants to the other that (a) such Party is an entity or corporation
duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized; (b) such
Party has the legal power and authority to execute, deliver and perform this Agreement; (c) the execution, delivery and performance
by such Party of this Agreement has been duly authorized; (d) this Agreement constitutes the legal, valid and binding obligation
of such Party, enforceable against such Party in accordance with its terms; and (e) the execution, delivery and performance
of this Agreement will not cause or result in a violation of any law, of such Party’s charter documents, or of any contract
by which such Party is bound.

 

IX.
COMPLIANCE WITH GOVERNMENTAL OBLIGATIONS

 

In exercising
its rights in this Agreement, LICENSEE shall fully comply, at its own expense, with all governmental requirements and binding requests
directed to it, and will provide all information and assistance necessary to comply with the governmental requests. Failure to
take necessary action and to comply with said requirements and requests shall be considered a material breach of this Agreement.
LICENSOR disclaims any obligations or liabilities arising under the license provisions of this Agreement if LICENSEE is charged
in a governmental action for not complying with or fails to comply with any governmental regulations.

 

X.
CONFIDENTIALITY

 

		10.1	During the course of negotiating this Agreement, the Parties may have exchanged confidential information
and may continue to exchange such information during the term of this Agreement With regard to the other Party’s Confidential
Information, the receiving Party must use the Confidential Information solely for purposes of fulfilling its obligations under
this Agreement and must safeguard the Confidential Information against disclosure to others with the same degree of care as each
Party exercises with their own confidential information of a similar nature, but in no event less than a reasonable degree of care.

 

		10.2	The obligations of the recipient of the Confidential Information under this Section X (CONFIDENTIALITY)
do not apply to information:

		a.	that is now, or becomes in the future, public knowledge other than through unauthorized acts or
omissions of the recipient Party;

		b.	that is lawfully obtained by the recipient Party from a third party without restrictions on use,
duplication or disclosure;

		c.	that the recipient Party can demonstrate by written records was previously known to the recipient
Party or is developed by the recipient Party without reference to the Confidential Information; or,

		d.	that is required to be disclosed by law, provided that the Party intending to make a disclosure
required by law will give written notification to the other Party prior to such disclosure.

 

		10.3	Confidential Information covered by this Section X (CONFIDENTIALITY) must be maintained as confidential
for a period of [...***...] after termination of this Agreement.

 

*Confidential Treatment Requested

 

    	7

    	 

    

 

		10.4	LICENSEE agrees LICENSOR and/or inventors may publish manuscripts, abstractsor give seminars presenting
the results of the research (by virtue of Section 2.3 herein) after the proposed publication or presentation has been notified
in writing to LICENSEE thirty (30) days before.

 

XI.
DISPUTE RESOLUTION

 

		11.1	This Agreement, including the performance and enforceability hereof, shall be governed by and construed
in accordance with the laws of Italy without regard to the conflict of law provisions found therein.

 

		11.2	Both Parties will use reasonable efforts to reach an amicable negotiated settlement of any dispute
concerning the interpretation or operation of this agreement. Disputes concerning this agreement shall not be litigated. If negotiation
fails to resolve a dispute within sixty (60) days, either Party can require binding arbitration under the AAA International
Arbitration Rules and this Article XI (provided that any inventor, sublicense, patent infringer, or other person or entity involved
in such dispute either is already bound to participate in the same binding arbitration process or agrees in writing to do so, i.e.,
a Party cannot be bound to arbitration to resolve a dispute that is or could also be the subject of a separate litigation proceeding).
If the Parties cannot agree within thirty (30) days on the choice of an arbitrator, each Party shall appoint its own arbitrator
and those arbitrators shall jointly appoint a chairperson of an arbitral tribunal. Each Party shall be afforded reasonable opportunity
for pre-arbitration discovery. An arbitral award shall not include punitive damages, costs, or interim measures. Each Party shall
pay its own costs and an equal share of all other costs of mediation and arbitration, except for the exceptional circumstance in
which an arbitral award may require the payment of all costs by a Party who has brought a plainly frivolous dispute. Unless otherwise
agreed by the Parties when the occasion arises, arbitration shall be held in Milan, Italy This provision survives the Termination
of this Agreement.

 

XII.
MISCELLANEOUS

 

		12.1	This Agreement sets forth the entire agreement between the parties concerning the subject matter
hereof and supersedes all previous and contemporaneous representations and agreements, written or oral. No amendment or modification
hereof shall be valid or binding upon the parties unless made in writing and signed on behalf of each party by an authorized representative.

 

		12.2	LICENSEE shall not assign or otherwise transfer, whether directly or indirectly, in whole or in
part this Agreement, voluntarily, involuntarily, or by any other means (except to an AFFILIATE, or by operation of law including
any merger or consolidation, substantial change in ownership or control of LICENSEE’s business), without the prior written
consent of LICENSOR, which consent shall not be unreasonably withheld. This restriction does not limit or restrict LICENSEE’s
rights under Sections 2.1 and 2.1 to sublicense. This Agreement shall bind the Parties, their successors and their permitted assigns.

 

		12.3	This Agreement shall not be binding upon the Parties until it has been signed below on behalf of
each Party by an authorized representative, in which event, it shall be effective as of the EFFECTIVE
DATE.

 

 

    	8

    	 

    

 

		12.4	Should any provision of this Agreement be held invalid, illegal or unenforceable, by a court or
other entity of competent jurisdiction, such provision shall be considered void. All other provisions, rights and obligations shall
remain enforceable.

 

		12.5	No failure or delay by a party in exercising any of its rights or remedies hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of any such right or remedy preclude any other or farther exercise
thereof of any other right or remedy. The rights and remedies of the parties provided in this Agreement are cumulative and not
exclusive of any rights or remedies provided by law.

 

		12.6	Headings used herein are for descriptive purposes only and shall not control or alter the meaning
of this Agreement as set forth in the text.

 

		12.7	This Agreement may be signed in counterparts, each of which together shall constitute one and the
same Agreement, binding on the parties as if each had signed the same document. Any facsimile transmission of this Agreement that
is signed by an authorized representative of a party is legally binding and enforceable and shall be recognized by the parties
as an original document, but the parties shall nevertheless make commercially reasonable efforts to obtain original signatures.

 

	 	 	 	 	 
	UNIVERSITA DEGLI STUDI DI	 	 	CAPRICOR INC.
	ROMA “LA SAPIENZA”	 	 	 	 
	 	 	 	 	 
	/s/ Renato Guarini	 	 	/s/ Eduardo Marbán
	 	 	 	By: Eduardo Marban, M.D., Ph.D.
	 By: Renato Guarini	 	 	 	 
	 	 	 	President
	 Rector	 	 	 	 
	 	 	 	(SEAL)
	 	 	 	 	 
	 	 	 	ATTEST:
	 	 	 	 	 
	 	 	 	By:	/s/ William
    E. Carlson
	 	 	 	 	William E, Carlson, Esquire Secretary

 

    	9

    	 

    

 

APPENDIX A

LICENSED PATENT RIGHTS

 

[...***...]

 

*Confidential Treatment Requested

 

    	10

    	 

    

 

 

[...***...]

 

*Confidential Treatment Requested

 

    	11

    	 

    

 

 

[...***...]

 

*Confidential Treatment Requested

 

    	12Exhibit
10.32

 

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 240.24b-2

 

 

EXCLUSIVE LICENSE
AGREEMENT

 

BETWEEN

 

THE JOHNS HOPKINS
UNIVERSITY

 

&

 

CAPRICOR, INC.

 

________________________

 

 

 

JHU Ref: DM –
4562

 

    	 

    	 

    

 

LICENSE AGREEMENT

 

THIS
EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland
corporation having an address at 3400 N. Charles Street, Baltimore, MD 21218-2695 (“JHU”) and CAPRICOR, INC., a Delaware
corporation having an address at 2415 Old Bosley Road, Lutherville, MD 21093 (“Company”), with respect to the following:

 

 

RECITALS

 

WHEREAS,
valuable inventions as identified by name and JHU reference numbers on Exhibit A attached hereto and incorporated herein
by this reference were developed during the course of research conducted by those individuals who are identified on Exhibit
A hereto as inventors by having their respective names underlined thereon (all hereinafter, "Inventors"); and

 

WHEREAS,
JHU has acquired through assignment all right, title, and interest, with the exception of certain retained rights by the United
States government, in said valuable inventions; and

 

WHEREAS,
as a center for research and education, JHU is interested in licensing PATENT RIGHTS (hereinafter defined) in a manner that will
benefit the public by facilitating the distribution of useful products and the utilization of new methods, but is without capacity
to commercially develop, manufacture, and distribute any such products or methods; and

 

WHEREAS,
Company desires to obtain exclusive rights under the PATENT RIGHTS in order to commercially develop, manufacture, use, and distribute
such products and processes throughout the world;

 

NOW THEREFORE, in consideration
of the premises and the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

 

ARTICLE 1

DEFINITIONS

 

All references to
particular Exhibits, Articles, or Paragraphs shall mean the Exhibits to, and Paragraphs and Articles of, this Agreement, unless
otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the
following meanings:

 

1.1“AFFILIATED
COMPANY” as used herein in either singular or plural shall mean any corporation, company, partnership, joint
venture or other entity, which controls, is controlled by or is under common control with Company. For purposes of this Paragraph
1.1, “control” shall mean the direct or indirect ownership of at least fifty percent (50%) of the voting stock or
other ownership interest of such entity.

 

    	Page 1

    	 

    

 

1.2“EFFECTIVE
DATE” of this License Agreement shall mean the date the last party hereto has executed this Agreement.

 

1.3“EXCLUSIVE
LICENSE” shall mean a grant by JHU to Company of its entire right and interest in the PATENT RIGHTS throughout the world,
subject (if and to the extent any NIH funds were used for the licensed invention) to rights retained by the United States government
in accordance with the Bayh-Dole Act of 1980 (established by P.L. 96-517 and amended by P.L. 98-620, codified at 35 USC §
200 et. seq. and implemented according to 37 CFR Part 401), and subject to the retained right of JHU to make, have made, provide,
and use for its and The Johns Hopkins Health Systems' nonprofit academic research purposes, LICENSED PRODUCT(S) and LICENSED SERVICE(S),
including the ability to distribute any biological material covered by the PATENT RIGHTS to non-commercial entities for nonprofit
academic research use as is customary in the scientific community; provided, however, that any transfer of such biological
material may only be made with advance notice to the Company and pursuant to the Materials Transfer Agreement attached
hereto as Exhibit B.

 

1.4“FINANCING
MILESTONE” shall mean Company’s raise of $1,000,000 (One Million Dollars) or more in equity and/or convertible
debt.

 

1.5“FIRST
COMMERCIAL SALE” shall mean the first sale of a LICENSED PRODUCT or a LICENSED SERVICE by Company, an AFFILIATED COMPANY
or a SUBLICENSEE for consideration in an arm’s-length transaction following recipient from the appropriate government agency
of marketing approval for such LICENSED PRODUCT or such LICENSED SERVICE.

 

1.6“KNOW-HOW”
shall mean (a) biological materials in JHU’s possession that were developed by Inventors of PATENT RIGHTS and which are disclosed
in PATENT RIGHTS, and any portions, progeny, or unmodified derivatives thereof and (b) any other tangible know-how in JHU’s
possession that may be necessary or useful for the effective exercise of the PATENT RIGHTS in the LICENSED FIELD.

 

1.7“LICENSED
FIELD” shall mean any and all commercial and research fields.

 

1.8“LICENSED
PRODUCT(S)” as used herein in either singular or plural shall mean any material, composition,
drug, or other product, the manufacture, use, or sale of which by Company, an AFFILIATED COMPANY, or a SUBLICENSEE would constitute,
but for the license granted to Company pursuant to this Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to infringe). 

 

1.9“LICENSED
SERVICE(S)” as used herein in either singular or plural shall mean the performance on behalf
of a third party by Company, an AFFILIATED COMPANY or a SUBLICENSEE of any method, including any drug discovery or screening, or
the manufacture 

of any
product or the use of any product or composition which would constitute, but for the license granted to Company pursuant to this
Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall include, but not be limited to, direct, contributory,
or inducement to infringe).

 

    	Page 2

    	 

    

 

1.10“NET
SALES” shall mean gross sales revenues and fees billed by Company, AFFILIATED COMPANIES,
and SUBLICENSEE(S) from the sale of LICENSED PRODUCT(S) less (a) trade discounts allowed; (b) amounts repaid or credited by reason
of refunds, returns, and recalls; (c) outbound transportation and delivery charges (including insurance premiums related thereto),
if separately included in the invoiced amount; (d) government-mandated retroactive price reductions; (e) amounts allowed for bad
debt; and (f) sales taxes, tariff duties, and other government charges (other than income taxes) related to the manufacture, use,
transportation, or sale of LICENSED PRODUCT(S). 

 

In
the event that Company, AFFILIATED COMPANIES, and SUBLICENSEE(S) sell LICENSED PRODUCT(S)
in combination with other active ingredients or substances or as part of a kit containing other component(s) (including, but not
limited to, devices for delivery), and such other ingredients, substances or components, if manufactured, used or sold by an unlicensed
party would not constitute an infringement of PATENT RIGHTS (collectively “Other Components”), then Net Sales for purposes
of royalty payments shall be calculated using one of the following methods: (x) if all LICENSED PRODUCT(S) and Other Components
contained in the combination are available separately, then NET SALES shall be calculated by multiplying the NET SALES of the combination
by the fraction A/A+B, where A is the invoice price of all LICENSED PRODUCT(S) in the combination and B is the invoice price of
all Other Components in the combination; (y) if the combination includes Other Components which are not sold separately (but all
LICENSED PRODUCT(S) contained in the combination are available separately), then NET SALES shall be calculated by multiplying the
NET SALES of the combination by the fraction A/C, where A is defined above and C is the invoice price of the combination; and (z)
if the LICENSED PRODUCT(S) and the Other Components in the combination are not sold or available separately, then NET SALES for
purposes of determining royalties on the combination shall be calculated by multiplying NET SALES of the combination by the fraction
D/D+E, where D is the fully burdened manufacturing cost of LICENSED PRODUCT(S) at the point of assembly into the combination and
E is the fully burdened manufacturing cost of the Other Components included in the combination at such point. 

 

In
the event any LICENSED PRODUCT(S) shall be sold by Company to an AFFILIATED COMPANY or among AFFILIATED COMPANIES for subsequent
resale to an unaffiliated third party, then the royalty due hereunder shall be based upon the greater of: (a) NET SALES received
by Company from the AFFILIATED COMPANY and (b) NET SALES received by the AFFILIATED COMPANY from the purchaser of such LICENSED
PRODUCT(S). 

 

In
the event that consideration in lieu of money is received by Company, AFFILIATED COMPANIES, or SUBLICENSEE(S) from the sale of
LICENSED PRODUCT(S) in an arms-length transaction, the fair market value of such consideration shall be included in the determination
of NET SALES for such sale. Such fair market value shall be determined by the Company, AFFILIATED COMPANY or SUBLICENSEE, as applicable,
in good faith.

 

    	Page 3

    	 

    

 

1.11“NET
SERVICE REVENUES” shall mean gross service revenues and fees billed by Company, AFFILIATED
COMPANIES and SUBLICENSEE(S) for the performance of LICENSED SERVICE(S) less (a) amounts allowed for bad debt and (b) sales and/or
use taxes and other government charges (other than income taxes) imposed upon and with specific reference to the LICENSED SERVICE(S).
In the event that Company, AFFILIATED COMPANIES or SUBLICENSEE(S) sell a LICENSED SERVICE(S) in combination with other services,
then NET SERVICE REVENUES for purposes of royalty payments shall be calculated by multiplying the NET SERVICE REVENUES of the combination
by the fraction A/A+B, where A is the invoice price of all LICENSED SERVICE(S) and B is the invoice price of all other services
in the combination. 

 

1.12“PATENT
RIGHTS” shall mean the patents and patent applications set forth in Exhibit A attached
hereto, together with any patents that issue on any of the patent applications set forth in Exhibit A, any reissues, reexaminations,
renewals, extensions, divisions, and continuations of the foregoing, any foreign counterparts to any of the foregoing, and any
other form of patent coverage (including, subject to the limitation below, continuations-in-part) claiming priority to any of the
foregoing patents and patent applications. Continuations-in-part are included to the extent that the subject matter of such continuation-in-part
application is described in and enabled by the disclosure of the initial JHU patent application.

 

1.13“SUBLICENSEE”
as used herein in either singular or plural shall mean any person or entity other than an AFFILIATED
COMPANY to which Company has granted a sublicense under this Agreement. 

 

 

ARTICLE 2

LICENSE GRANT

 

2.1Grant.
Subject to the terms and conditions of this Agreement, JHU hereby grants to Company an EXCLUSIVE
LICENSE to make, have made, use, import, offer for sale, and sell the LICENSED PRODUCT(S) and to provide the LICENSED SERVICE(S)
in the United States and worldwide under the PATENT RIGHTS in the LICENSED FIELD. In order to facilitate Company’s development
of LICENSED PRODUCTS and LICENSED SERVICES,
JHU additionally grants Company a non-exclusive license to KNOW-HOW in the LICENSED FIELD. In furtherance of such license,
JHU shall (a) reduce to writing and provide to Company, upon Company’s reasonable and occasional request, utilization procedures,
best practices, protocols, and the like and (b) promptly provide Company, upon Company’s reasonable request, reasonable quantities
of biological materials covered by the PATENT RIGHTS.

 

2.2Sublicense.
Company may sublicense others under this Agreement with prior notice to JHU, and shall provide
a copy of each such sublicense agreement to JHU promptly after it is executed. For the avoidance of doubt, Company need not seek
JHU’s consent prior to executing a sublicense agreement. Each sublicense shall be consistent with the terms of this Agreement.

 

    	Page 4

    	 

    

 

2.3 Government
Rights. Company acknowledges that the United States government has retained certain rights under
the PATENT RIGHTS and that Company may be subject to certain laws and regulations applicable to the grant/contract award under
which the associated inventions were made. Company shall comply with such laws and regulations to the extent applicable. 

 

2.4“Financing
Milestone” Condition Precedent. The effectiveness of the grant under Article 2 of this
Agreement is conditioned upon Company achieving the FINANCING MILESTONE on or before that day that is nine (9) months after the
EFFECTIVE DATE (or upon any later date as Company and JHU may hereafter agree in writing). Upon Company’s achievement of
the FINANCING MILESTONE, Company shall so inform JHU in writing and this Agreement shall be deemed to be effective as of the EFFECTIVE
DATE. Prior to the achievement of the FINANCING MILESTONE, Articles 4, 8, 9, and 10 shall apply. In the event that the FINANCING
MILESTONE is not achieved prior to the deadline stated in this Paragraph 2.4, this Agreement shall thereupon and thereafter be
null and void except for any pre-termination obligations of Company under Paragraphs 3.8 and 4.1.

 

 

ARTICLE 3

FEES, ROYALTIES, & PAYMENTS

 

3.1License
Fee. Company shall pay to JHU, within thirty (30) days of the later of (a) the EFFECTIVE DATE
of this Agreement and (b) Company achieving the FINANCING MILESTONE, the initial license fee set forth in Exhibit C. JHU
will not submit an invoice for the license fee, which is nonrefundable and shall not be credited against royalties or other fees.

 

3.2Annual Maintenance
Fee. Company shall pay to JHU a nonrefundable, non-creditable annual maintenance fee as set forth
in Exhibit C. This annual maintenance fee shall be due within thirty (30) days of each anniversary of the EFFECTIVE DATE
beginning with the first anniversary.

 

3.3Minimum
Annual Royalties. Company shall pay to JHU minimum annual royalties in the amounts set forth
in Exhibit C. These minimum annual royalties shall be due within thirty (30) days of each anniversary of the EFFECTIVE DATE
beginning with the first anniversary. Any such minimum annual royalties shall be credited against running royalties due pursuant
to Paragraph 3.4(a) during such anniversary year (i.e., running from anniversary date to anniversary date) and (b) against subsequent
years; provided, however, in respect to applying such payments as credits against subsequent years, that such credit not
reduce the amount otherwise payable to JHU in any royalty payment period by more than [...***...] and with any amount
unable to be credited by operation of the preceding clause being carried forward into each subsequent royalty payment period until
the full credit has been realized.

 

3.4Royalties.
Company shall pay to JHU, on a country-by-country basis, a running royalty on NET SALES and NET SERVICE REVENUES at the
rates set forth in Exhibit C. All non-US income taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S)
sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. Only
one royalty shall be due and payable for the manufacture, use, or sale of a LICENSED PRODUCT or LICENSED SERVICE,
irrespective of the number of claims within the PATENT RIGHTS that would be infringed by the manufacture, use, or sale of
such LICENSED PRODUCT or LICENSED SERVICE.

 

 

*Confidential Treatment Requested

 

    	Page 5

    	 

    

 

3.5Exclusions
from Revenue. Neither of the following shall be included in NET SALES or NET
SERVICE REVENUES: (a) the transfer of a LICENSED PRODUCT to an AFFILIATED
COMPANY for sale by such AFFILIATED COMPANY in a transaction that will be
royalty-bearing, and (b) the transfer of a LICENSED PRODUCT to, or provision of
a LICENSED SERVICE for, a third party without consideration in connection with the
development or testing of a LICENSED PRODUCT or LICENSED
SERVICE. In addition, NET SALES and NET
SERVICE REVENUES shall be reduced by [...***...] in connection with the sale of a LICENSED
PRODUCT or provision of a LICENSED SERVICE to or on behalf of the United
States government in respect of any rights that may be retained by the United States government under the PATENT
RIGHTS in the LICENSED FIELD.

 

3.6Sublicense
Consideration. Company shall pay to JHU the percentage of Sublicense Consideration as set forth in Exhibit C. For purposes
of this Paragraph 3.6, the term “Sublicense Consideration” shall mean consideration of any kind received by the Company
or AFFILIATED COMPANIES from SUBLICENSEE(S) in consideration for the grant of a sublicense under the PATENT RIGHTS, including up-front
licensing fees, milestone payments, and any premium paid by the SUBLICENSEE(S) over Fair Market Value for stock of the Company
or an AFFILIATED COMPANY in consideration for such sublicense, but excluding license maintenance fees, running royalties, funding
for product development, research work, clinical studies and regulatory approvals performed by or for the Company or AFFILIATED
COMPANIES or third parties pursuant to a specific agreement including a performance plan and commensurate budget, and equity investments
at no more than Fair Market Value. The term "Fair Market Value" shall mean, for a publicly-traded security, the average
closing price of that security (as reported by the securities exchange or market on which it is listed) during twenty (20) trading
day period ending on the trading day prior to the announcement of its purchase by the SUBLICENSEE(S) or, for a security that is
not publicly traded, the fair market value of such security as determined in good faith by the Board of Directors of the Company
or AFFILIATED COMPANY that issued the shares.

 

3.7Payment Reduction
If Rights Non-Exclusive. If Company has a joint ownership interest in a particular PATENT RIGHT in the LICENSED FIELD or if
JHU is not the assignee under the rights of all of the inventors of the invention(s) claimed in a particular PATENT RIGHT, then
(a) all payments due to JHU pursuant to Paragraphs 3.2 through 3.6 hereof shall be reduced by [...***...] and (b) Company
shall be entitled to credit [...***...] of all payments previously paid to JHU pursuant to Paragraphs 3.1 through 3.6
hereof (to the extent not already adjusted by operation of clause (a) above) against future payment obligations to JHU hereunder
(as such obligations shall be adjusted by operation of clause (a) above).

 

3.8Patent
Cost Reimbursement. In addition to the provisions of Paragraph 4.1 below, notwithstanding the
condition precedent set forth in Paragraph 2.4, Company will reimburse JHU for all reasonable, documented, out-of-pocket costs
incurred up to and including the EFFECTIVE DATE of this Agreement in connection with the preparation, filing, prosecution, and
maintenance of the PATENT RIGHTS in the LICENSED FIELD. Such reimbursement shall be made in three (3) equal annual installments,
with the first such payment due within thirty (30) days of the EFFECTIVE DATE of this Agreement. 

 

 

*Confidential Treatment Requested

 

 

    	Page 6

    	 

    

 

3.9.Milestone
Payments. Company shall pay JHU within one hundred twenty (120) days after the achievement of
each of the milestones such payments as are set forth in Exhibit C.

 

3.10Form of
Payment. All payments under this Agreement shall be made in U.S. Dollars by the Company. Checks
are to be made payable to “The Johns Hopkins University". Wire transfers may be made through:

 

Bank:

 

[...***...]

 

Wire info: 

 

[...***...]

 

 

If needed for international
wires:

 

[...***...]

 

 

 

Company
shall be responsible for any and all costs associated with wire transfers. 

 

3.11Late Payments.
In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the tenth day
following the due date thereof, at two (2) percentage points above the prime interest rate quoted by The Wall Street Journal
(Eastern Edition) on the date said payment is due, the interest being compounded annually; provided however, that
in no event shall said interest rate exceed the maximum applicable legal interest rate.

 

 

*Confidential Treatment Requested

 

    	Page 7

    	 

    

 

ARTICLE 4

PATENT PROSECUTION, MAINTENANCE, &
INFRINGEMENT

 

4.1Prosecution
& Maintenance. JHU shall prepare, file, prosecute, and maintain all patents and patent applications under the PATENT RIGHTS
upon authorization of Company and Company shall be exclusively licensed thereunder. Title to all such patents and patent applications
shall reside in JHU. JHU shall have full and complete control over all patent matters in connection therewith under the PATENT
RIGHTS; provided, however, that JHU shall instruct patent counsel to cross-copy Company with copies of all documents (or
drafts thereof) pertaining to the preparation, filing, prosecution, or maintenance of the PATENT RIGHTS so as to enable Company
to have a meaningful opportunity to review and comment thereon. JHU will consider and incorporate reasonable comments received
from Company. Company shall reimburse JHU, within forty-five (45) days of the receipt of an invoice from JHU, for all reasonable,
documented, out-of-pocket costs incurred by JHU after the EFFECTIVE DATE in connection with the preparation, filing, prosecution,
and maintenance of the PATENT RIGHTS in the LICENSED FIELD. Company will provide payment authorization to JHU at least one (1)
month before an action is due, provided that Company has received timely notice of such action from JHU. Failure to provide authorization
can be considered by JHU as a Company decision not to authorize an action. In any country where Company elects not to have a patent
application filed or to pay expenses associated with preparing, filing, prosecuting, or maintaining a patent application or patent,
JHU may prepare, file, prosecute, and/or maintain the patent application or patent at its own expense and for its own exclusive
benefit and Company thereafter shall not be licensed under such patent or patent application in such country.

 

4.2Notification.
Each party will notify the other promptly in writing of any known or suspected third party infringement
of any PATENT RIGHTS or if any action for a declaration of non-infringement or invalidity of PATENT RIGHTS is made by a third party,
or if any allegation of infringement of third party patents is made against either party, an AFFILIATED COMPANY, or a SUBLICENSEE
as a result of the manufacture, use or sale of a LICENSED PRODUCT or provision of a LICENSED SERVICE.

 

4.3Infringement.

 

(a)Company
shall have the first right to respond to any challenge or infringement of the PATENT RIGHTS at its own expense and shall at all
times keep JHU informed as to the status thereof. Company may, in its sole judgment and at its own expense, institute suit against
any such infringer or alleged infringer and control, settle, and defend such suit in a manner consistent with the terms and provisions
hereof and recover, for its account, any damages, awards, or settlements resulting therefrom, subject to Paragraph 4.4. This right
to sue for infringement shall not be used in an arbitrary or capricious manner. JHU agrees to be included as a party plaintiff
in any such action and shall otherwise reasonably cooperate in any such action at Company's expense.

 

(b)If,
within ninety (90) days of providing to or receiving from Company notice of third party infringement of the PATENT RIGHTS pursuant
to the preceding paragraph, Company does not exercise its first right to initiate legal action or initiate discussions to avert

legal
action (by license or otherwise), then JHU may, in its sole judgment and at its own expense, take steps to enforce any patent and
control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover, for its own account,
any damages, awards, or settlements resulting therefrom; provided, however, that JHU shall give good faith consideration
to the position of Company in declining to bring any action in the first instance.

 

    	Page 8

    	 

    

 

4.4Recovery.
Any recovery of monetary damages by Company under Paragraph 4.3(a) shall be allocated to the
parties in the following manner: (a) first, Company shall be reimbursed for all costs and expenses incurred by it in connection
with such action; (b) any remaining compensatory damages shall be divided [...***...]. 

 

4.5Right to
Sublicense Infringers. Company shall have the sole right, subject to the terms and conditions
hereof, to sublicense any alleged infringer for future use of the PATENT RIGHTS in the LICENSED FIELD.

 

 

ARTICLE 5

OBLIGATIONS OF THE PARTIES

 

5.1Reports.
Company shall provide to JHU within thirty (30) days of the end of each calendar quarter after the FIRST COMMERCIAL SALE, a written
report to JHU of the amount of LICENSED PRODUCT(S) sold, and LICENSED SERVICE(S) sold, the total NET SALES and NET SERVICE REVENUES
of such LICENSED PRODUCT(S) and LICENSED SERVICE(S), and the running royalties due to JHU as a result of NET SALES and NET SERVICE
REVENUES by Company, AFFILIATED COMPANIES and SUBLICENSEE(S) thereof. Payment of any such royalties due shall accompany such report.
The report of sales and royalties due shall be substantially in the format of the sales and royalty report form given in Exhibit
D. Prior to the FIRST COMMERCIAL SALE, Company shall submit to JHU, on an annual basis, a full written report describing Company's,
AFFILIATED COMPANIES’ or any SUBLICENSEE'S technical efforts towards meeting its obligations under the terms of this Agreement.

 

5.2Records.
Company shall make and retain, for a period of three (3) years following the period of each
report required by Paragraph 5.1, true and accurate records, files and books of account containing all the data reasonably required
for the full computation and verification of sales and other information required in Paragraph 5.1. Such books and records shall
be in accordance with generally accepted accounting principles consistently applied. Company shall permit the inspection and copying
of such records, files and books of account by JHU or its agents during regular business hours upon ten (10) business days' written
notice to Company. Such inspection shall not be made more than once each calendar year. All costs of such inspection and copying
shall be paid by JHU, provided that if any such inspection shall reveal that an error has been made in the amount equal
to ten percent (10%) or more of such payment, such costs shall be borne by Company. Company shall include in any agreement with
its AFFILIATED COMPANIES or its SUBLICENSEE(S) which permits such party to make, use or sell the LICENSED PRODUCT(S) or
provide LICENSED SERVICE(S), a provision requiring such party to retain records of sales of LICENSED PRODUCT(S) and records of
LICENSED SERVICE(S) and other information as required in Paragraph 5.1 and permit JHU to inspect such records as required by this
Paragraph.

 

 

 

*Confidential Treatment Requested

    	Page 9

    	 

    

 

5.3Diligence.
Company shall exercise commercially reasonable and diligent efforts to develop and to introduce
the LICENSED PRODUCT(S) and LICENSED SERVICE(S) into the commercial market as soon as practicable, consistent with sound and reasonable
business practice and judgement; thereafter, until the expiration of the Agreement, Company shall endeavor to keep LICENSED PRODUCT(S)
and LICENSED SERVICE(S) reasonably available to the public. Company shall also exercise commercially
reasonable efforts to ensure that the PATENT RIGHTS can be commercialized as broadly and as speedily in the LICENSED FIELD as good
scientific and business judgement would deem possible. 

 

5.4Patent Acknowledgement.
Company agrees that all packaging containing individual LICENSED PRODUCT(S) sold
by Company, AFFILIATED COMPANIES and SUBLICENSEE(S) will be marked with the number of the applicable patent(s) licensed hereunder
in accordance with each country's patent laws, or Company shall be responsible for any damages lost as a result of the failure
to so mark. 

 

 

ARTICLE 6

REPRESENTATIONS

 

6.1Representations
by JHU. JHU warrants that, to the best of its knowledge following due inquiry, it has all right,
title, and interest in and to the PATENT RIGHTS with the exception of certain retained rights of the United States government.
JHU warrants that it has not licensed or assigned any right or interest in or to the PATENT RIGHTS to a third party in the LICENSED
FIELD, that it has the right to grant the rights and licenses granted hereunder and such rights have been validly granted, and
that such grant does not require the consent of a third party. JHU does not warrant the validity of any patents or that practice
under such patents or use of KNOW-HOW shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 6.1, COMPANYAGREES
THAT THE PATENT RIGHTS AND KNOW-HOW ARE PROVIDED "AS IS", AND THAT JHU MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT
TO THE PERFORMANCE OF LICENSED PRODUCT(S) AND LICENSED SERVICE(S) INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL VIABILITY.
JHU DISCLAIMS ALL WARRANTIES WITH REGARD TO PRODUCT AND SERVICE LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL
WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION
OF THIS AGREEMENT, JHU ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU AND INVENTORS, FOR DAMAGES, INCLUDING,
BUT NOT LIMITED TO, DIRECT, 

INDIRECT,
SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS' FEES, AND COURT COSTS (EVEN IF JHU HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCT AND SERVICE
LICENSED UNDER THIS AGREEMENT. COMPANY, AFFILIATED COMPANIES AND SUBLICENSEE(S) ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS
OR DAMAGE CAUSED BY A PRODUCT AND SERVICE MANUFACTURED, USED, OR SOLD BY COMPANY, ITS SUBLICENSEE(S) AND AFFILIATED COMPANIES WHICH
IS A LICENSED PRODUCT(S) OR LICENSED SERVICE(S) AS DEFINED IN THIS AGREEMENT.

 

    	Page 10

    	 

    

 

ARTICLE 7

INDEMNIFICATION

 

7.1Indemnification.
JHU and the Inventors will have no legal liability exposure to third parties if JHU does
not license the LICENSED PRODUCT(S) and LICENSED SERVICE(S), and any royalties JHU and the Inventors may receive is not adequate
compensation for such legal liability exposure. Therefore, JHU requires Company to protect JHU and Inventors from such exposure
to the same manner and extent to which insurance, if available, would protect JHU and Inventors. Furthermore, JHU and the Inventors
will not, under the provisions of this Agreement or otherwise, have control over the manner in which Company or its AFFILIATED
COMPANIES or its SUBLICENSEE(S) or those operating for its account or third parties who purchase LICENSED
PRODUCT(S) or LICENSED SERVICE(S) from any of the foregoing entities, develop, manufacture, market or practice the inventions
of LICENSED PRODUCT(S) and LICENSED SERVICE(S). Therefore, Company, AFFILIATED COMPANY and SUBLICENSEE shall indemnify, defend
with counsel reasonably acceptable to JHU, and hold JHU, The Johns Hopkins Health Systems, their present and former trustees,
officers, Inventors of PATENT RIGHTS, agents, faculty, employees and students harmless as against any judgments, fees, expenses,
or other costs arising from or incidental to any product liability or other lawsuit, claim, demand or other action brought as
a consequence of the practice of said inventions by any of the foregoing entities, whether or not JHU or said Inventors, either
jointly or severally, is named as a party defendant in any such lawsuit, except those which arise from any use of the PATENT RIGHTS
or KNOW-HOW resulting from the use by JHU of the rights JHU has retained under this Agreement. JHU shall notify Company promptly
of any claims and Company shall have the right to control the defense, settlement or compromise of any such claim, and Company
shall have no obligation to an indemnified party hereunder for a claim that is settled or compromised without Company’s
prior written consent and whether or not JHU or the Inventors are alleged to be negligent or otherwise responsible for any injuries
to persons or property. Practice of the inventions covered by LICENSED PRODUCT(S) and LICENSED SERVICE(S), by an AFFILIATED COMPANY
or an agent or a SUBLICENSEE(S) or a third party on behalf of or for the account of Company or by a third party who purchases
LICENSED PRODUCT(S) and LICENSED SERVICE(S) from Company, shall be considered Company's practice of said inventions for purposes
of this Paragraph. The obligation of Company to defend and indemnify as set out in this Paragraph shall survive the termination
of this Agreement, shall continue even after assignment of rights and responsibilities to an affiliate or sublicensee, and shall
not be limited by any other limitation of liability elsewhere in this Agreement.

 

ARTICLE 8

CONFIDENTIALITY

 

8.1Confidentiality.
If necessary, the parties will exchange information that they consider to be confidential. The
recipient of such information agrees to accept the disclosure of said
information which is marked as confidential at the time it is sent to the recipient, and to employ all reasonable efforts to maintain
the information secret and confidential, such efforts to be no less than the degree of care employed by the recipient to preserve
and safeguard its own confidential information. The information shall not be disclosed or revealed to anyone except employees
of the recipient who have a need to know the information and who have entered into a secrecy agreement with the recipient under
which such employees are required to maintain confidential the proprietary information of the recipient and such employees shall
be advised by the recipient of the confidential nature of the information and that the information shall be treated accordingly.
Notwithstanding the foregoing, Company shall have the right to disclose confidential information of JHU to a third party that
undertakes obligations of confidentiality and non-use with respect to such information at least as restrictive as Company’s
obligations hereunder.

 

    	Page 11

    	 

    

 

The
obligations of this Paragraph shall also apply to AFFILIATED COMPANIES and/or SUBLICENSEE(S) provided such information by Company.
JHU's, Company's, AFFILIATED COMPANIES, and SUBLICENSEE's obligations under this Paragraph shall extend until three (3) years after
the termination of this Agreement. 

 

8.2Exceptions.
The recipient's obligations under Paragraph 8.1 shall not extend to any part of the information:

 

		a.	that can be demonstrated to have been in the public domain or
publicly known and readily available to the trade or the public prior to the date of the disclosure; or 

 

		b.	that can be demonstrated from written records to have been in
the recipient's possession or readily available to the recipient from another source not under obligation of secrecy to the disclosing
party prior to the disclosure; or

 

		c.	that becomes part of the public domain or publicly known by publication
or otherwise by some means other than an unauthorized act by the recipient; or

 

		d.	that is demonstrated from written records to have been developed
by or for the receiving party without reference to confidential information disclosed by the disclosing party; or 

 

		e.	that is required to be disclosed by law, government regulation
or court order.

 

8.3Right to
Publish. JHU may publish manuscripts, abstracts or the like describing the PATENT RIGHTS, the
inventions contained therein and KNOW-HOW, provided such publication is first submitted to Company for review, comment, and consideration
of appropriate action. JHU shall submit such manuscripts, abstracts or the like to Company for review at least thirty (30) days
prior to the date of submission for publication or submission of the abstract or oral disclosure. Company shall notify JHU within
thirty (30) days of receipt of such submission whether it appears that any patent applications
may need to be filed in connection with obtaining or maintaining the PATENT RIGHTS. Written publication or other disclosure by
JHU shall be deferred to permit the filing of any necessary patent applications, provided said deferral shall in no event exceed
ninety (90) days from the date of receipt by Company of said disclosure. Further, confidential information of Company as defined
in Paragraph 8.1 shall not be included in any manuscript, abstract or the like without first obtaining written approval from Company,
which consent may be withheld in Company’s sole discretion.

 

    	Page 12

    	 

    

 

ARTICLE 9

TERM & TERMINATION

 

9.1Term.
The term of this Agreement shall commence on the EFFECTIVE DATE and shall continue, in each country,
until the date of expiration of the last to expire patent included within PATENT RIGHTS in that country or if no patents issue
then for a term of [...***...] from the EFFECTIVE DATE of this Agreement.

 

9.2Termination
By Either Party.

 

(a)This
Agreement may be terminated by either party, in the event that the other party (a) files a petition under the Bankruptcy Act, makes
an assignment for the benefit of creditors, voluntarily has a receiver appointed for it or a substantial part of its assets, or
otherwise takes advantage of any statute or law designed for relief of debtors or (b) fails to perform or otherwise breaches any
of its obligations hereunder, if, following the giving of notice by the terminating party of its intent to terminate and stating
the grounds therefor, the party receiving such notice shall not have cured the failure or breach within thirty (30) days. In no
event, however, shall such notice or intention to terminate be deemed to waive any rights to damages or any other remedy which
the party giving notice of breach may have as a consequence of such failure or breach. 

 

(b)All
rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section
365(n) of the U.S. Bankruptcy Code, as amended (the “Code”), licenses of rights to "intellectual property"
as defined under Section 101 of the Code. The parties agree that Company is a licensee of such rights under this Agreement and
shall retain and may fully exercise all rights under the Code. The parties further agree that, in the event of the commencement
of a bankruptcy proceeding by or against JHU or its assignee under the Code, Company shall be entitled to (x) take control of the
patent prosecution of the Patent Rights and (y) receive a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property. Such intellectual property and embodiments, if not already
in Company's possession, shall be, within ten (10) days of the commencement of such proceeding, delivered to it upon JHU's receipt
of a request therefore, unless JHU (or a trustee on behalf of JHU) elects to continue to perform all of its obligations under this
Agreement. Nothing herein shall constitute Company's acquiescence or agreement that all or any portion of this Agreement is subject
to rejection.

 

9.3Termination
by Company. Company may terminate this Agreement and the licenses granted herein, for any reason, upon giving JHU sixty (60)
days written notice.

 

 

*Confidential Treatment Requested

    	Page 13

    	 

    

 

9.4Obligations
and Duties upon Termination. If this Agreement is terminated pursuant to Paragraphs 9.2(a) or 9.3, both parties shall be released
from all obligations and duties imposed or assumed hereunder to the extent so terminated, except as expressly provided to the contrary
in this Agreement. Upon termination, both parties shall cease any further use of the confidential information disclosed to the
receiving party by the other party. Termination of this Agreement, for whatever reason, shall not affect the obligation of either
party to make any payments for which it is liable prior to or upon such termination. Termination shall not affect JHU's right to
recover unpaid royalties or fees or reimbursement for patent expenses incurred pursuant to Paragraph 4.1 prior to termination.
Upon termination, Company shall submit a final royalty report to JHU and any royalty payments and unreimbursed patent expenses
due JHU shall become immediately payable, and all tangible manifestations of KNOW-HOW shall be returned to the appropriate Inventors
or destroyed. Furthermore, upon termination of this Agreement, all rights in and to the PATENT RIGHTS and KNOW-HOW shall revert
immediately to JHU at no cost to JHU. Upon termination of this Agreement, any SUBLICENSEE(S) shall become a direct licensee of
JHU, provided that JHU’s obligations to SUBLICENSEE(S) are no greater than JHU’s obligations to Company under this
Agreement. Company shall provide written notice of such to each SUBLICENSEE(S) with a copy of such notice provided to JHU.

 

ARTICLE 10

MISCELLANEOUS

 

10.1Use of
Name. Company shall not use the name of The Johns Hopkins University or The Johns Hopkins Health
System or any of its constituent parts, such as the Johns Hopkins Hospital or any contraction thereof or the name of Inventors
of PATENT RIGHTS in any advertising, promotional or sales literature or fundraising documents without prior written consent from
an authorized representative of JHU, except that Company may advise any other party that it is licensed by JHU under this Agreement.
Company shall allow at least five (5) business days notice of any proposed public disclosure for JHU's review and comment or to
provide written consent. Notwithstanding the foregoing, Company shall have the right to use the name of JHU without JHU’s
prior written consent where such use is required by law, rule or regulation (e.g., federal and state securities laws). In
addition, once JHU has consented to a particular disclosure, Company shall not be required to seek JHU’s consent to make
the same disclosure in a subsequent document.

 

10.2No
Partnership. Nothing in this Agreement shall be construed to create any agency, employment, partnership,
joint venture or similar relationship between the parties other than that of a licensor/licensee. Neither party shall have any
right or authority whatsoever to incur any liability or obligation (express or implied) or otherwise act in any manner in the name
or on the behalf of the other, or to make any promise, warranty or representation binding on the other. 

 

10.3Notice
of Claim. Each party shall give the other party or its representative immediate notice of any
suit or action filed, or prompt notice of any claim made, against them arising out of the performance of this Agreement. 

 

    	Page 14

    	 

    

 

10.4Product
Liability. Prior to initial human testing or first commercial sale of any LICENSED PRODUCT(S)
or LICENSED SERVICE(S) as the case may be in any particular country, Company shall establish and maintain, in each country in which
Company, an AFFILIATED COMPANY or SUBLICENSEE(S) shall test or sell LICENSED PRODUCT(S) and LICENSED SERVICE(S), product liability
or other appropriate insurance coverage in the minimum amount of [...***...] per claim (with an industry reasonable “annual
aggregate” dollar limit to be agreed upon by JHU and Company) and will annually present evidence to JHU that such coverage
is being maintained. Upon JHU's request, Company will furnish JHU with a Certificate of Insurance of each product liability insurance
policy obtained. JHU shall be listed as an additional insured in Company's said insurance policies. If such Product Liability insurance
is underwritten on a ‘claims made’ basis, Company agrees that any change in underwriters during the term of this Agreement
will require the purchase of ‘prior acts’ coverage to ensure that coverage will be continuous throughout the term of
this Agreement. If JHU and Company are unable to reach agreement as to the industry reasonable “annual aggregate” dollar
limit, either JHU or Company may request arbitration. Upon such request, within fifteen (15) days thereafter, the parties shall
agree upon a single arbitrator to review the matter, but if they cannot so agree, they shall each name an arbitrator, and the two
arbitrators shall select a third arbitrator. One of the arbitrators shall be a member of the Association of University Technology
Managers. The parties shall submit the issue to the arbitrators on written brief only, there shall be no formal hearing. Briefs
shall be filed within thirty (30) days of selection of the arbitrator, or the panel, and shall include the party’s suggestion
of the aggregate amount, and the basis therefore. 

 

10.5Governing
Law. This Agreement shall be construed, and legal relations between the parties hereto shall
be determined, in accordance with the laws of the State of Maryland applicable to contracts solely executed and wholly to be performed
within the State of Maryland without giving effect to the principles of conflicts of laws. Any disputes between the parties to
the Agreement shall be brought in the state or federal courts of Maryland.

 

10.6Notice.
All notices or communication required or permitted to be given by either party hereunder shall be deemed sufficiently given if
mailed by registered mail or certified mail or sent by overnight courier, such as Federal Express, to the other party at its respective
address set forth below or to such other address as one party shall give notice of to the other from time to time hereunder. Mailed
notices shall be deemed to be received on the third business day following the date of mailing. Notices sent by overnight courier
shall be deemed received the following business day. 

 

	If to Company:	Capricor, Inc.	 
	 	2415 Old Bosley Road	 
	 	Lutherville, MD 21093	 
	 	Attn: President	 
	 	 	 
	 	 	 
	with a copy to:	Shapiro Sher Guinot & Sandler 	 
	 	36 S. Charles Street, Suite 2000	 
	 		 
	 		 

 

 

 

*Confidential Treatment Requested

    	Page 15

    	 

    

 

	 	Baltimore, MD 21201
	 	Attn: [...***...]
	 	 
	 	 
	If to JHU:	Johns Hopkins Technology
    Transfer
	 	100 North Charles Street, 5th
    Floor
	 	Baltimore, MD 21201
	 	Attn: [...***...],
    Executive Director

 

10.7Compliance
with All Laws. In all activities undertaken pursuant to this Agreement, JHU and Company each
covenant and agree that it will comply in all material respects with applicable Federal, state and local laws and statutes as may
be in effect at the time of performance and all valid rules, regulations and orders thereof regulating such activities. 

 

10.8Successors
and Assigns. Neither this Agreement nor any of the rights or obligations created herein, except
for the right to receive any remuneration hereunder, may be assigned by either party, in whole or in part, without the prior written
consent of the other party, except that either party shall be free to assign this Agreement in connection with a merger, consolidation,
or sale of all or substantially all of its assets without the consent of the other. Any consents requested hereunder shall not
be unreasonably withheld or delayed. This Agreement shall bind and inure to the benefit of the successors and permitted assigns
of the parties hereto. 

 

10.9No Waivers;
Severability. No waiver of any breach of this Agreement shall constitute a waiver of any other
breach of the same or other provision of this Agreement, and no waiver shall be effective unless made in writing. Any provision
hereof prohibited by or unenforceable under any applicable law of any jurisdiction shall as to such jurisdiction be deemed ineffective
and deleted herefrom without affecting any other provision of this Agreement. It is the desire of the parties hereto that this
Agreement be enforced to the maximum extent permitted by law, and should any provision contained herein be held by any governmental
agency or court of competent jurisdiction to be void, illegal and unenforceable, the parties shall negotiate in good faith for
a substitute term or provision which carries out the original intent of the parties.

 

10.10Entire
Agreement; Amendment. Company and JHU acknowledge that they have read this entire Agreement and
that this Agreement, including the attached Exhibits, constitutes the entire understanding and contract between the parties hereto
and supersedes any and all prior or contemporaneous oral or written communications with respect to the subject matter hereof, all
of which communications are merged herein. It is expressly understood and agreed that (i) there being no expectations to the contrary
between the parties hereto, no usage of trade, verbal agreement or another regular practice or method dealing within any industry
or between the parties hereto shall be used to modify, interpret, supplement, or alter in any manner the express terms of this
Agreement; and (ii) this Agreement shall not be modified, amended or in any way altered except by an instrument in writing signed
by both of the parties hereto. 

 

 

 

*Confidential Treatment Requested

    	Page 16

    	 

    

 

10.11Delays
or Omissions. Except as expressly provided herein, no delay or omission to exercise any right,
power or remedy accruing to any party hereto, shall impair any such right, power or remedy to such party nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or in any similar breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

10.12Force
Majeure. If either party fails to fulfill its obligations hereunder (other than an obligation
for the payment of money), when such failure is due to an act of God, or other circumstances beyond its reasonable control, including
but not limited to fire, flood, civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said failure
shall be excused for the duration of such event and for such a time thereafter as is reasonable to enable the parties to resume
performance under this Agreement. 

 

10.13Further
Assurances. Each party shall, at any time and from time to time, upon the reasonable request
of the other party, execute and deliver to the other such instruments and documents and shall take such actions as may be required
to more effectively carry out the terms, purposes and intent of this Agreement. 

 

10.14Survival.
Articles 6, 7 and 8 and Paragraphs 3.10, 4.1, 9.4, 10.1, 10.3, 10.5, 10.6, 10.13 and 10.14 (and related definitions) shall survive
the expiration or any termination of this Agreement.

 

10.15No Third
Party Beneficiaries. Nothing in this Agreement shall be construed as giving any person, firm,
corporation or other entity, other than the parties hereto and their successors and permitted assigns, any right, remedy or claim
under or in respect of this Agreement or any provision hereof. 

 

10.16Headings.
Article and paragraph headings are for convenient reference and not a part of this Agreement. All Exhibits are incorporated herein
by this reference. 

 

10.17Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which when taken together
shall be deemed but one instrument.

 

 

[Signatures
on Following Page.]

 

    	Page 17

    	 

    

 

IN
WITNESS WHEREOF, this Exclusive License Agreement shall take effect as of the EFFECTIVE DATE, when it has been executed below by
the duly authorized representatives of the parties. 

 

	THE JOHNS HOPKINS UNIVERSITY	 	CAPRICOR, INC.
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	By: 	/s/ Jill A. Tarzian Sorensen	 	By: 	/s/ Eduardo Marbán
	 	 Jill A. Tarzian Sorensen, J.D.	 	 	Eduardo Marbán, M.D.
	 	 Executive Director, JHTT	 	 	President
	 	 	 	 	 
	June 21, 2006	 	June 22, 2006
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	[SEAL]
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	William E. Carlson
	 	 	 	 	William E. Carlson, Esq.
	 	 	 	 	Secretary

 

EXHIBIT A. PATENT RIGHTS.

EXHIBIT B.MATERIAL TRANSFER
AGREEMENT.

EXHIBIT C.LICENSE FEE
& ROYALITIES.

EXHIBIT
D. SALES & ROYALTY REPORT FORM.

 

    	Page 18

    	 

    

 

EXHIBIT A

 

PATENT RIGHTS

 

 

[...***...]

 

 

 

*Confidential Treatment Requested

    	Page 19

    	 

    

 

EXHIBIT B

 

MATERIAL TRANSFER AGREEMENT

 

Johns Hopkins University School of
Medicine

MATERIAL TRANSFER AGREEMENT

FOR NON-PROFIT RECIPIENTS

 

1.Parties to this
Agreement

 

	Providing Scientist:	
         

         

	
         

        Providing Organization:
	
         

        Johns Hopkins University

         

	
         

        Address:
	
        Johns Hopkins Technology Transfer

        100 North Charles Street, 5th
        Floor

        Baltimore, MD 21201

         

         

			

 

	“PROVIDER” shall mean the Providing Organization through its employee, the Providing Scientist.
	 	 
	Recipient Scientist:	 
	
         

        Recipient Organization:
	 
	
         

        Address:
	 
	 	 
	“RECIPIENT” shall mean the Recipient Organization through its employee, the Recipient Scientist.

 

2.Material(s)

 

	Material(s) provided:	 

 

			“MATERIAL(S)” means the provided materials described above and any Progeny and
Unmodified Derivatives thereof. Progeny is an unmodified descendant from the provided material, such as virus from virus, cell
from cell, or organism from organism. Unmodified Derivatives are substances created by the RECIPIENT which constitute an unmodified
functional subunit or product expressed by the provided material, such as subclones of unmodified cell lines, purified or fractionated
subsets of the provided material, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by
a hybridoma cell line. MATERIAL(S) shall not include: (a) Modifications, or (b) other substances created by the recipient through
the use of the MATERIAL(S) which are not Modifications, Progeny, or Unmodified Derivatives. Modifications are materials made by
the RECIPIENT which contain/incorporate the MATERIAL(S).

 

    	Page 20

    	 

    

 

			The MATERIAL(S), including, but not limited to, MATERIAL(S) contained or incorporated in
Modifications, are the sole property of the PROVIDER and are made available as a service to the research community. RECIPIENT acknowledges
that certain intellectual property rights claiming the MATERIAL(S) have been granted to Capricor, Inc. (“Capricor”),
and that except as expressly provided in this Agreement, no rights are provided to RECIPIENT under any patents, patent applications,
trade secrets or other proprietary rights of PROVIDER or Capricor.

 

3.Research

 

			The RECIPIENT agrees that THE MATERIAL(S) SHALL NOT BE USED IN HUMAN SUBJECTS, IN CLINICAL
RESEARCH, OR FOR DIAGNOSTIC PURPOSES INVOLVING HUMAN SUBJECTS. The PROVIDER agrees that the MATERIAL(S) were not obtained from
human subjects.

 

			The RECIPIENT agrees to use the MATERIAL(S) in compliance with all applicable statutes and
regulations, including the Public Health Service and National Institutes of Health regulations and guidelines such as, for example,
those relating to research involving the use of animals and/or recombinant DNA.

 

			The RECIPIENT agrees that the MATERIAL(S) will be used solely for internal research purposes
in the laboratory of the Recipient Scientist and under his/her direct supervision. 

 

			The RECIPIENT agrees that the MATERIAL(S) will not be used for any Commercial Purpose. Commercial
Purpose shall mean the sale, lease, license, or other transfer of the MATERIAL(S) or Modifications to a for-profit organization.
Commercial Purposes shall also include uses of the MATERIAL(S) or Modifications by any organization, including RECIPIENT, to perform
contract research or other research sponsored by a for-profit entity, to screen compound libraries, to produce or manufacture products
for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL(S) or
Modifications to a for-profit organization. 

 

			The RECIPIENT agrees that the MATERIAL(S) and Modifications (except as set forth below) will
not be transferred to any third party without the PROVIDER’s written consent. Nothing in this Agreement shall preclude the
PROVIDER from transferring the MATERIAL(S) to other interested third parties for commercial or research purposes. The RECIPIENT
shall have the right, without restriction, to distribute to third parties substances created by the RECIPIENT through the use of
the MATERIAL(S) provided those substances are not Progeny or Unmodified Derivatives. The RECIPIENT may transfer Modifications to
not-for-profit research institutions under a material transfer agreement containing terms substantially similar to those contained
in this Agreement.

 

If RECIPIENT’s
research with MATERIAL or Modifications results in a patentable invention (“Invention”), RECIPIENT agrees promptly
to disclose the Invention to PROVIDER and Capricor on a confidential basis. Inventorship will be determined in accordance with
United States patent law (whether or not patentable) and ownership shall follow inventorship. In the case of a joint invention
between PROVIDER and RECIPIENT or among PROVIDER, RECIPIENT and Capricor (“Joint Invention”), the applicable parties
agree to negotiate in good faith an exclusive license agreement for such Joint Invention with Capricor. If RECIPIENT decides not
to pursue the further development of an Invention or Joint Invention hereunder, then PROVIDER or Capricor may elect to pursue the
patenting or commercial development of said Invention or Joint Invention at its/their sole discretion. PROVIDER, RECIPIENT and
Capricor shall each have the right to use such Inventions and Joint Inventions for internal research purposes without payment of
any license fees or royalties. In addition, Capricor shall have an exclusive, first option to obtain an exclusive, worldwide, royalty-bearing
commercial license for each Invention or Joint Invention conceived solely by RECIPIENT or jointly by PROVIDER and RECIPIENT, with
such option to be valid for a period of six (6) months from the date on which Capricor received written notice of the disclosure
of such Invention or joint Invention.

 

    	Page 21

    	 

    

 

4.Publications

 

			This Agreement shall not be interpreted to prevent or delay the publication of research findings
resulting from the use of the MATERIAL(S). The Recipient Scientist agrees to provide appropriate acknowledgement of the source
of the MATERIAL(S) in all publications resulting from the use of the MATERIAL(S). Recipient Scientist further agrees to furnish
PROVIDER and Capricor with a copy of the manuscript or abstract disclosing such findings prior to submission thereof and not less
than thirty (30) days prior to their publication or disclosure. PROVIDER and Capricor shall promptly provide RECIPIENT with any
comments relating to said publication or presentation and RECIPIENT may proceed with said publication or presentation after taking
due consideration of such comments. If no response is received from PROVIDER or Capricor within thirty (30) days of the date of
the proposed publication or disclosure was received by PROVIDER and Capricor, respectively, it will be conclusively presumed that
the publication or disclosure may proceed without delay. If PROVIDER or Capricor determines that the proposed publication or disclosure
contains patentable subject matter that requires protection, then PROVIDER or Capricor may request the delay of the presentation
or disclosure for a period of time not to exceed ninety (90) days for the purpose of allowing the pursuit of such patent protection.
Patent applications shall be prepared, filed, prosecuted and maintained by the owner(s) of the subject intellectual property unless
and until an alternative arrangement is mutually agreed upon by all of the owners of such intellectual property and Capricor. 

 

5.Miscellaneous

			

			The MATERIAL(S) are understood to be experimental in nature and may have hazardous properties.
The PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS
OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE
ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

 

Except to the
extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of
the MATERIAL(S). Neither PROVIDER (including, but not limited to, its directors, trustees, officers, employees, students, and agents,
as applicable) nor Capricor will be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against
the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted
by law when caused by the gross negligence or willful misconduct of the PROVIDER or Capricor.

 

			Neither party shall use the name of the other or any contraction or derivative thereof or
the name(s) of the other party's faculty members, employees, or students, as applicable, in any advertising, promotional, sales
literature, or fundraising documents without prior written consent from the other party.

 

    	Page 22

    	 

    

 

In the event that
the MATERIAL(S) are not received by the RECIPIENT, this Agreement shall terminate ninety (90) days after the Effective Date and
neither party shall have any further obligations or responsibilities under this Agreement. Otherwise, this Agreement will terminate
one (1) year from the Effective Date. Notwithstanding the foregoing, those provisions which by their nature should survive such
termination, shall survive such termination, provided however, that no obligations under this Agreement shall survive beyond
five (5) years following the Effective Date. Promptly upon the one year termination date, RECIPIENT, unless otherwise instructed
by PROVIDER, agrees to destroy the MATERIAL(S).

 

The parties to this Agreement,
the RECIPIENT and the PROVIDER, hereby indicate their agreement to the terms of this Agreement by affixing the signature below
of an appropriate representative or officer who is specifically authorized to execute documents of this type. The “Effective
Date” of this Agreement shall be the date that the last party hereto signs this Agreement.

 

 

	
        RECIPIENT ORGANIZATION

         

         
	 	PROVIDING ORGANIZATION
	By:	 	 	By:	 
	
         

        Name:
	
         

         
	 	
         

        Name:
	 
	Title:	 	 	Title:	 

 

The Recipient Scientist and Providing Scientist, by affixing
their signatures below, acknowledge that they have read, understood, and agree to comply with the terms of this Agreement.

 

 

	
        Recipient Scientist

         

         
	 	Providing Scientist
	By:	 	 	By:	 
	
         

        Name:
	
         

         
	 	
         

        Name:
	
         

         

	Title:	 	 	Title:	 
	
         

        Date:
	 	 	
         

        Date:
	 

 

    	Page 23

    	 

    

 

EXHIBIT C

 

LICENSE FEE & ROYALTIES

 

[...***...]

 

	Development Milestone	Payment
	
        Successful
        completion of a full Phase I clinical study [...***...]

         

         
	$100,000
	
        [...***...]

         
	
        [...***...]

        

 

 

 

 

*Confidential Treatment Requested

    	Page 24

    	 

    

 

	
        [...***...]

         
	 
	
        [...***...]

        

         
	[...***...]
	Full FDA market approval.	$1,000,000
    (which shall
    be paid in four (4) equal, quarterly installments, the first being on such 120th day).

 

 

 

*Confidential Treatment Requested

 

    	Page 25

    	 

    

 

EXHIBIT D

 

QUARTERLY SALES & ROYALTY REPORT

 

FOR LICENSE AGREEMENT BETWEEN CAPRICOR,
INC. AND

THE JOHNS HOPKINS UNIVERSITY DATED

JUNE ____, 2006

 

FOR PERIOD OF ______________
TO ______________

 

TOTAL ROYALTIES DUE FOR THIS
PERIOD $___________

 

	
         

        PRODUCT

        ID
	
         

         

        PRODUCT NAME
	
         

        *JHU REFERENCE
	
         

        1st COMMERCIAL SALE DATE
	
         

        TOTAL NET

        SALES/SERVICES
	
         

        ROYALTY RATE
	
         

        AMOUNT

        DUE

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

*
Please provide the JHU Reference Number or Patent Reference

 

This report
format is to be used to report quarterly royalty statements to JHU. It should be placed on Company letterhead and accompany any
royalty payments due for the reporting period. This report shall be submitted even if no sales are reported. 

 

    	Page 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]